Amarin Corporation presented new findings from the REDUCE-IT trial showing that risk-weighted apolipoprotein B (RW-apoB) better identifies residual cardiovascular risk in statin-treated patients with elevated triglycerides than traditional lipid markers. This metric accounts for the higher atherogenicity of triglyceride-rich lipoproteins and lipoprotein(a), improving risk prediction beyond LDL cholesterol. The results support using RW-apoB in clinical settings to better stratify risk and guide additional treatments like icosapent ethyl, which has proven benefits in reducing cardiovascular events. These insights align with recent guideline updates recommending icosapent ethyl for high-risk patients with persistent triglyceride elevation despite statin therapy.
Veea Inc. has announced the commercial release of VeeaONE, a full-stack AI infrastructure platform that integrates edge-to-cloud hardware and software. The platform supports VeeaWare middleware on NVIDIA Jetson and x86/Arm servers, enabling secure, l...
Virtuals Protocol has introduced customizable tokenized indexes on the Robinhood Chain, allowing users to combine multiple assets into a single token. This innovation enables users to create and manage their own asset baskets and earn fees when other...
US spot Bitcoin ETFs saw net inflows of $107.8 million on Wednesday, while Ethereum ETFs attracted $53.8 million, signaling renewed institutional interest in crypto funds. Since their launch in January 2024, Bitcoin ETFs have accumulated over $51 bil...
Kaia has signed a strategic partnership with Xilo Labs to integrate Mochi, an onchain asset management platform, into Kaia's ecosystem. This collaboration allows users to invest stablecoins into diversified portfolios backed by tokenized real-world a...
Bitcoin's price surged to nearly $65,000 following softer-than-expected U.S. inflation data for June, easing fears of Federal Reserve rate hikes. However, on-chain data reveals two main groups of investors—long-term holders who bought near last year'...
